K-V Takes Fight Over Makena Knockoffs To ITC

Law360, New York (October 24, 2012, 4:37 PM EDT) -- K-V Pharmaceutical Co. on Tuesday filed a complaint with the U.S. International Trade Commission seeking to block pharmacies from importing an ingredient used to produce cheaper versions of its premature-birth prevention drug Makena, after its attempts to block compounded versions of the drug stalled in federal court.

K-V claims that pharmacies in the U.S. are unlawfully importing Makena's active ingredient, 17-hydroxyprogesterone caproate, or HPC, to produce inferior and potentially dangerous versions of the preterm-birth treatment. The St. Louis-based drugmaker has requested a temporary exclusion order and...
To view the full article, register now.